Interim results from stomp study of siga's tecovirimat in treatment of mpox announced

New york, dec. 10, 2024 (globe newswire) -- the national institutes of health's (nih) national institute of allergy and infectious diseases (niaid) today announced results from an interim analysis of the study of tecovirimat for human mpox virus (stomp) clinical trial (nct05534984). niaid reported that siga's tecovirimat, a highly targeted antiviral treatment, did not demonstrate efficacy in time to skin and mucosal lesion resolution compared to placebo in patients with mild to moderate clade ii mpox. based on this and additional analyses, the study data safety and monitoring board (dsmb) recommended to stop enrolling patients in the randomized arms of the study. niaid accepted this recommendation and subsequently decided to take a similar action in the open label arm of this study, which included severe and at-risk of developing severe disease patients.  data analysis is not yet complete for primary endpoint subgroups and detailed secondary and exploratory endpoints.
SIGA Ratings Summary
SIGA Quant Ranking